Synektik (SNTP) Q3 2025 earnings summary

Executive summary

• Achieved 24% year-over-year growth in total revenue for Q3 2024, driven by strong performance in medical equipment and IT services, and a 51% increase in radio-pharmaceuticals revenue.

• EBITDA from continuing operations rose 31% year-over-year in Q3, with margin improvement to 27%.

• For the nine months ended June 2025, total revenue was stable at PLN 482.1m, with EBITDA up 12% to PLN 122.5m and net income up 12% to PLN 71.3m.

• Strategic focus on recurring revenue streams and expansion in medical therapy devices and radio-pharmaceuticals.

Financial highlights

• Q3 2024 revenue: PLN 154.2m (up 24% YoY); 9M 2024 revenue: PLN 482.1m (down 0.2% YoY).

• Q3 2024 EBITDA: PLN 41.6m (up 31% YoY); 9M 2024 EBITDA: PLN 122.5m (up 12% YoY).

• Q3 2024 net income: PLN 23.7m (up 42% YoY); 9M 2024 net income: PLN 71.3m (up 12% YoY).

• Operating cash flow for 9M 2024: PLN 41.3m; net cash decreased by PLN 38.9m due to dividend and investment outflows.

• Dividend payout of PLN 70.4m in the period.

Outlook and guidance

• Management expects continued growth in medical equipment, IT, and recurring service revenues, supported by new product launches and expansion in Central and Eastern Europe.

• Anticipates further growth in radio-pharmaceuticals, driven by portfolio expansion and market development.

• No formal financial guidance issued for FY2024.